Marginal structural models with dose-delay joint-exposure for assessing variations to chemotherapy intensity

Stat Methods Med Res. 2019 Sep;28(9):2787-2801. doi: 10.1177/0962280218780619. Epub 2018 Jun 19.

Abstract

Marginal structural models are causal models designed to adjust for time-dependent confounders in observational studies with dynamically adjusted treatments. They are robust tools to assess causality in complex longitudinal data. In this paper, a marginal structural model is proposed with an innovative dose-delay joint-exposure model for Inverse-Probability-of-Treatment Weighted estimation of the causal effect of alterations to the therapy intensity. The model is motivated by a precise clinical question concerning the possibility of reducing dosages in a regimen. It is applied to data from a randomised trial of chemotherapy in osteosarcoma, an aggressive primary bone-tumour. Chemotherapy data are complex because their longitudinal nature encompasses many clinical details like composition and organisation of multi-drug regimens, or dynamical therapy adjustments. This manuscript focuses on the clinical dynamical process of adjusting the therapy according to the patient's toxicity history, and the causal effect on the outcome of interest of such therapy modifications. Depending on patients' toxicity levels, variations to therapy intensity may be achieved by physicians through the allocation of either a reduction or a delay of the next planned dose. Thus, a negative feedback is present between exposure to cytotoxic agents and toxicity levels, which acts as time-dependent confounders. The construction of the model is illustrated highlighting the high complexity and entanglement of chemotherapy data. Built to address dosage reductions, the model also shows that delays in therapy administration should be avoided. The last aspect makes sense from the cytological point of view, but it is seldom addressed in the literature.

Keywords: Causal inference; bivariate exposure; marginal structural models; osteosarcoma; therapy delay.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Bone Neoplasms / drug therapy*
  • Child
  • Child, Preschool
  • Confounding Factors, Epidemiologic
  • Drug Administration Schedule*
  • Female
  • Humans
  • Longitudinal Studies
  • Male
  • Models, Statistical*
  • Osteosarcoma / drug therapy*
  • Prognosis
  • Randomized Controlled Trials as Topic